Delaware Supreme Court Reduces Johnson & Johnson Damages Award
Delaware's Supreme Court has reduced a $1 billion damages award against Johnson & Johnson in a case involving Auris Health shareholders. The ruling maintains key breach-of-contract findings while potentially lowering J&J's financial liability by hundreds of millions.
Insights:
In a significant legal development, the Delaware Supreme Court has unanimously overturned part of a $1 billion damages award against Johnson & Johnson , stemming from a dispute with Auris Health shareholders over a 2019 acquisition agreement. The ruling, issued on Monday, January 12, 2026, reduces the pharmaceutical giant's potential liability by hundreds of millions of dollars, while upholding the core breach-of-contract findings from the original trial.
The dispute centers on Johnson & Johnson'sacquisition of Auris Health in 2019, valued at $3.4 billion. Shareholders, represented by Fortis Advisors, accused the company of failing to adequately support Auris's iPlatform technology and delaying regulatory approvals. Further allegations included claims that Johnson & Johnsonfraudulently induced Auris to accept milestone-contingent payments instead of upfront acquisition payments.
